Copertina

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Darcy Quinn Holt, Peter R. Ebeling
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
di: Guofu Mao, et al.
Pubblicazione: (2026)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
di: Keith Bodger
Pubblicazione: (2025)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
di: Jakob B. Seidelin
Pubblicazione: (2024)

Editorial: Getting to the Heart of the Matter in IBD
di: Ashwin N. Ananthakrishnan
Pubblicazione: (2025)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
di: Katherine L. Stone, et al.
Pubblicazione: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
di: Daniele Noviello, et al.
Pubblicazione: (2025)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
di: Xueneng Yang, et al.
Pubblicazione: (2025)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
di: Olga M. Nardone, et al.
Pubblicazione: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
di: Alice S. Day, et al.
Pubblicazione: (2025)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
di: James L. Alexander, et al.
Pubblicazione: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
di: Shabari Shenoy, et al.
Pubblicazione: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
di: Simone Chin, et al.
Pubblicazione: (2025)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
di: Fahim Ebrahimi, et al.
Pubblicazione: (2024)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
di: Natassia Tan, et al.
Pubblicazione: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
di: Samantha Baillie, et al.
Pubblicazione: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Editorial: HBV Integration: A Possible Key Driver in the Course of Patients With Chronic HBV Infection Under Viral Suppression
di: Hidenori Toyoda
Pubblicazione: (2025)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
di: Maria Ling Lundström, et al.
Pubblicazione: (2024)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
di: Qin Ning, et al.
Pubblicazione: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
di: Giovanni Cammarota, et al.
Pubblicazione: (2024)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
di: Adam S. Faye, et al.
Pubblicazione: (2025)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
di: Xinli Chen, et al.
Pubblicazione: (2024)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
di: Chachrit Khunsriraksakul, et al.
Pubblicazione: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
di: Arta Aliu, et al.
Pubblicazione: (2024)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
di: Saad Khan, et al.
Pubblicazione: (2024)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
di: Kelly Torosian, et al.
Pubblicazione: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
di: Dhruv Ahuja, et al.
Pubblicazione: (2025)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Runqi Wang, et al.
Pubblicazione: (2026)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
di: Changhu Sun, et al.
Pubblicazione: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
di: Emily Stephenson, et al.
Pubblicazione: (2026)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
di: Anish J. Kuriakose Kuzhiyanjal, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
di: Maxim S. Petrov
Pubblicazione: (2026)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
di: Amanda Ricciuto, et al.
Pubblicazione: (2024)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)